Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Perrigo Company    PRGO

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 5 410 M
EBIT 2016 1 430 M
Net income 2016 436 M
Debt 2016 5 102 M
Yield 2016 0,52%
Sales 2017 5 653 M
EBIT 2017 1 527 M
Net income 2017 472 M
Debt 2017 4 311 M
Yield 2017 0,74%
P/E ratio 2016 72,80
P/E ratio 2017 27,89
EV / Sales2016 3,48x
EV / Sales2017 3,19x
Capitalization 13 716 M
More Financials
Company
Perrigo Co. Plc engages in the production of over-the-counter consumer goods and specialty pharmaceutical products.It operates through the following segments: Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals, and Specialty Sciences.The CHC segment includes... 
Sector
Pharmaceuticals
Calendar
10/20Earnings Release
More about the company
Surperformance© ratings of Perrigo Company
Trading Rating : Investor Rating :
More Ratings
Latest news on PERRIGO COMPANY
09/12 Perrigo, Colgate-Palmolive and Raptor rise; Citigroup slips
09/12 Activist Starboard demands rapid changes at Perrigo
09/12 PERRIGO : Starboard buys stake in drugmaker Perrigo, wants shakeup
09/12 S&P 500 MOVERS : Aal, prgo
09/12DJPERRIGO : Starboard Prods Perrigo -- WSJ
09/12DJStarboard Value Takes 4.6% Stake in Perrigo
09/12DJPERRIGO : Starboard Value Takes 4.6% Stake in Perrigo -- Update
09/12DJPERRIGO : Starboard Value Takes 4.6% Stake in Perrigo, Worth Nearly $600 Million
09/09 PERRIGO CO PLC : Other Events, Financial Statements and Exhibits (form 8-K)
09/01 GLOBAL LORATADINE MARKET 2016 : Morepen, Perrigo, Ultratech, Hetero Drugs Ltd, M..
More news
Sector news : Pharmaceuticals - NEC
08:49aDJPFIZER : Scraps Plan to Break Up Company -- WSJ
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
09/26DJPfizer Throws Out Plan to Split Into Two Companies
More sector news : Pharmaceuticals - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 20
Average target price 103 $
Spread / Average Target 7,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John T. Hendrickson President, Chief Executive Officer & Director
Mary Lauren Brlas Chairman
Judy L. Brown Executive VP, Chief Financial & Accounting Officer
Thomas Farrington Chief Information Officer & Executive VP
Gerald K. Kunkle Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PERRIGO COMPANY13 716
JOHNSON & JOHNSON14.66%322 232
ROCHE HOLDING LTD.-11.18%215 081
NOVARTIS AG-8.70%211 231
PFIZER INC.4.21%204 049
MERCK & CO., INC.17.66%171 858
More Results